Title: Glucagon-like peptide-1 receptor activation and mental health: a drug-target Mendelian

randomization study

Short title: GLP-1R and mental health

Authors:

Guoyi Yang, PhD[a,b*], Stephen Burgess, PhD[c,d], C Mary Schooling, PhD[a,e]

[a] School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong,

Hong Kong, China

[b] Department of Medicine, Perelman School of Medicine, University of Pennsylvania,

Philadelphia, USA

[c] MRC Biostatistics Unit, University of Cambridge, Cambridge, UK

[d] British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health

and Primary Care, University of Cambridge, Cambridge, UK

[e] Graduate School of Public Health and Health Policy, City University of New York, New

York, USA

[*]**Corresponding author: Guoyi Yang, PhD**

Postal address: 1/F, Patrick Manson Building, 7 Sassoon Road, Pokfulam, Hong Kong

Email address: yanggy@connect.hku.hk

Telephone: +852 98147624

ORCID: 0000-0002-4387-386X

Word count: 3514

The number of tables: 0

The number of figures: 4

Abstract

Concerns have been raised about the psychiatric safety of glucagon-like peptide-1 receptor
(GLP-1R) agonists, but trial evidence suggests that they ameliorate depressive symptoms. We
aimed to assess the associations of GLP-1R activation with mental health well-being and the
risk of mental health disorders and substance use disorders. We performed drug-target
Mendelian randomization and colocalization analyses using the largest relevant genome-wide
association studies and replicated in FinnGen. After correcting for multiple comparisons,
genetically predicted lower body mass index (BMI) via GLP-1R activation was associated
with a better well-being spectrum (0.06 standard deviation [95% confidence interval 0.03-
0.08]), lower risk of depression (odds ratio 0.83 [0.74-0.94]), and lower risk of bipolar
disorder (odds ratio 0.61 [0.47-0.79]) per 1-kg/m^2 decrease in BMI. There was also suggestive
evidence that genetically predicted lower BMI via GLP-1R activation was associated with
lower risk of substance use disorders. These associations were stronger than the associations
for genetically predicted lower BMI and lower glycated hemoglobin (HbA1c) based on
genome-wide variants. The posterior probabilities of colocalization of BMI and each outcome
at the *GLP1R* gene were 59.3% for the well-being spectrum, 3.8% for depression, and 45.9%
for bipolar disorder. However, the posterior probabilities of colocalization were > 80% for the
well-being spectrum and bipolar disorder when conditioning on the presence of a variant
associated with the outcome. This study provides genetic evidence that GLP-1R activation is
associated with better mental health well-being and lower risk of bipolar disorder, possibly
beyond its effect on BMI and HbA1c.

47   (Word count: 246)

49   **Keywords:** bipolar disorder, depression, glucagon-like peptide-1 receptor, Mendelian

50   randomization, mental health

Introduction

Glucagon-like peptide-1 receptor (GLP-1R) agonists reduce body weight and blood glucose.[1]

Randomized controlled trials (RCTs) have shown cardiovascular and mortality benefits of

GLP-1R agonists.[2,3] GLP-1R agonists act on the hindbrain, the hypothalamus, and vagal

afferents to suppress food intake and reduce body weight.[4-6] Anti-obesity drugs affecting

central nervous systems could have psychiatric effects. For example, the combination of

phentermine and topiramate increases depression and anxiety.[7] Rimonabant was withdrawn

from the market due to serious psychiatric adverse events.[8] In contrast, the combination of

naltrexone and bupropion improves depression[9] and substance use disorder.[10]

Concerns have been raised about the risk of suicidal ideation and self-injury in people using

GLP-1R agonists.[11] However, RCTs showed that GLP-1R agonists moderately reduced

depressive symptoms in people who are overweight or obese[12] and in people with type 2

diabetes.[13] Animal,[14,15] observational,[16,17] and genetic studies[18] suggested potential benefits of

GLP-1R agonists in alcohol use disorder, but RCTs yielded contradictory evidence showing

benefits or null effects.[19,20] Early-stage trials are on-going to investigate the efficacy of GLP-

1R agonists in individuals with mental illnesses[21] and substance use disorders.[22] A better

understanding of the association of GLP-1R activation, the intended target of GLP-1R

agonists, with mental health has implications for informing their psychiatric safety and

potential repurposing opportunities.

To address this gap, we used Mendelian randomization (MR), an instrumental variable

analysis with genetic instruments, to obtain less confounded estimates than conventional

observational studies.[23] We used MR to assess the associations of GLP-1R activation with

mental health outcomes including the well-being spectrum, mental health disorders, and

substance use disorders. We further investigated whether any associations were explained by

lowering body mass index (BMI) or lowering glycated hemoglobin (HbA1c).

Subjects and Methods

Ethics approval and consent to participate

All the analyses were conducted using publicly available summary statistics, which does not

require ethical approval. Participants of the original studies of publicly available summary

statistics provided informed consent.

Study design

MR relies on the instrumental variable assumptions of relevance (the genetic instruments

should be related to the exposure), independence (no common cause of the genetic

instruments and the outcome exists), and exclusion restriction (the genetic instruments should

be independent of the outcome given the exposure).[23] This MR study took advantage of the

largest relevant publicly available genome-wide association studies (GWASs) (eTable 1).

First, we assessed the associations of GLP-1R activation predicted by *GLP1R* variants with

mental health outcomes including the well-being spectrum, mental health disorders, and

substance use disorders. We compared these associations with the associations for lower BMI

and lower HbA1c predicted by genome-wide variants. Second, we performed colocalization

analyses to examine whether any associations found for GLP-1R activation were driven by a

shared causal variant affecting both BMI or HbA1c and the outcome at the *GLP1R* gene.[24]

Where possible, we conducted sex-specific analyses, because women are more likely to have

depression than men,[25] but boys are more likely to develop neurodevelopmental disorders

than girls.[26]

Genetic instruments

We selected genetic instruments for GLP-1R activation based on their associations with

downstream traits related to drug target effects (BMI and HbA1c), because this approach

reduces the risk of the variant-outcome association being lost or confounded by pleiotropic

effects.[27] We obtained genetic associations with BMI ($N = 806,834$) from a meta-analysis of

the UK Biobank and GIANT[28] and with HbA1c ($N = 344,182$) from a GWAS of the UK

Biobank.[29] We considered these two sets of instruments separately, because they might

represent distinct mechanisms.[30] For primary analyses, we extracted variants in or near (+-

1Mb) the *GLP1R* gene that were uncorrelated ($r^2 < 0.001$) and genome-wide significantly (*p*

value $< 5 \times 10^{-8}$) associated with BMI to mimic BMI-related mechanisms. We used the same

approach based on their associations with HbA1c to select genetic variants mimicking

HbA1c-related mechanisms. For sensitivity analyses, we used a less stringent significance

threshold for instrument selection (p value $< 1\times10^{-5}$). For comparison, we also extracted

genetic instruments for BMI and HbA1c from across the genome (genome-wide variants) that

were uncorrelated (r^2 <0.001) and genome-wide significantly (p value $<5\times10^{-8}$) associated

with BMI and HbA1c, respectively.

We used coronary artery disease (CAD) and all-cause mortality as positive control outcomes,

because RCTs have shown that GLP-1R agonists reduce cardiovascular events and death.[2,3]

We obtained genetic associations with CAD (181,522 cases/984,168 controls) from a meta-

analysis of the CARDIoGRAMplusC4D consortium and the UK Biobank.[31] We obtained

genetic associations with parental mortality (609,139 cases/403,101 controls), determined by

parental attained age and their alive/dead status, from a meta-analysis of the UK Biobank and

LifeGen as a measure of all-cause mortality,[32] because it has greater power than participant's

mortality.

Genetic associations with mental health outcomes

We obtained sex-combined and sex-specific genetic associations with mental health outcomes

from the largest relevant publicly available GWASs (eTable 1).[29,33-47] Primary outcomes

included the well-being spectrum, mental health disorders (depression, bipolar disorder, post-

traumatic stress disorder (PTSD), schizophrenia, anorexia nervosa, attention deficit

hyperactivity disorder (ADHD), autism spectrum disorder, and Tourette's syndrome), and

substance use disorders. Secondary outcomes included four dimensions of mental health well-

being (life satisfaction, positive affect, neuroticism, and depressive symptoms) and subtypes

of mental health disorders (postpartum depression and bipolar disorder I and II) and substance

use disorders (cannabis use disorder and alcohol dependence). Secondary outcomes also

included the Alcohol Use Disorders Identification Test (AUDIT) total score, score for alcohol

consumption, and score for alcohol problems. We obtained genetic associations with relevant

outcomes from the FinnGen R12 for replication,[48] where possible. Genetic associations with

binary outcomes obtained using linear regression were transformed into odds ratio (OR) using

an established approximation.[49]

MR analysis

We used the F-statistic to assess instrument strength, approximated by the square of SNP-

exposure association divided by the square of its standard error.[50] An F-statistic larger than 10

suggests weak instrument bias is unlikely. We aligned SNPs on the same allele for exposure

and outcome, and used proxy SNPs ($r^2 > 0.8$), where possible, when SNPs were not available

in the outcome GWAS. We calculated Wald estimates by dividing genetic association with

outcome by genetic association with exposure. We obtained MR estimates by meta-analyzing

Wald estimates using inverse variance weighting (IVW) with fixed effects for three SNPs or

fewer and random effects for four SNPs or more.[51] To assess the robustness of IVW estimates,

we conducted sensitivity analyses using the weighted median,[52] MR Egger,[53] and MR using

the robust adjusted profile score (MR-RAPS).[54] We used the Cochran's Q statistic[55] to test

heterogeneity in Wald estimates and the MR Egger intercept[53] to assess directional pleiotropy.

We used the Steiger filtering to identify the SNPs explaining more variance in the outcome

than in the exposure (p value < 0.05).[56] We conducted sensitivity analyses excluding the SNPs

identified to assess whether MR estimates were affected by reverse causation. We used a

Bonferroni-corrected significance level of $\alpha=0.05/10=0.005$ given ten primary outcomes. We

considered nominally significant associations (p value <0.05) that did not reach Bonferroni-

corrected significance as suggestive evidence. We tested differences by sex using a two-sided

z-test.[57]

Colocalization

We performed pairwise colocalization analyses in a Bayesian framework to assess whether

any associations found for GLP-1R activation were driven by a shared causal variant affecting

both BMI or HbA1c and the outcome or were confounded by linkage disequilibrium.[24] We

included variants (minor allele frequency >0.1%) in or near (+- 1Mb) the *GLP1R* gene. We set

the prior probabilities as recommended, that is 10^{-4} for a variant associated with BMI or

HbA1c, 10^{-4} for a variant associated with the outcome, and 10^{-5} for a variant associated with

both traits.[24] We assessed the posterior probability of several hypotheses, including H_0 (no

association with either trait), H_1, (association with BMI or HbA1c only); H_2, (association with

the outcome only); H_3, (associations of two independent variants and one for each trait); H_4

(associations of one shared variant with both traits).[24] A posterior probability of H_4 larger than

0.80 suggests colocalization.[24] The power to detect colocalization is low when the variants are

not strongly associated with the outcome, so we also calculated the posterior probability of

colocalization (H_4) conditional on the presence of a variant associated with the outcome as

$H_4/(H_2 + H_3 + H_4)$.[58] We reported the posterior probabilities of H_0-H_4 and conditional H_4 and

the variant with the largest posterior probability of being the shared causal variant.

We also used the Hypothesis Prioritisation for multi-trait Colocalization (HyPrColoc)[59] to

assess colocalization across multiple traits identified for GLP-1R activation. We set the prior

probability for a variant associated with at least one trait as 10^{-4} and the conditional prior

probability for a variant associated with an additional trait given that the variant is associated

with at least one other trait as 0.02.[59] We reported clusters of putatively colocalized traits and

the posterior probability of colocalization.

All statistical analyses were conducted using R version 4.2.1 and the packages "ieugwasr",

"TwoSampleMR", "MendelianRandomization", "mr.raps, "metafor", "coloc", and

"hyprcoloc".

Results

Genetic instruments

For primary analyses, we used two *GLP1R* SNPs (rs17757975 and rs4714290) genome-wide

significantly associated with BMI to predict the impact of GLP-1R activation as indicated by

lower BMI; we used one *GLP1R* SNP (rs10305518) genome-wide significantly associated

with HbA1c to predict the impact of GLP-1R activation as indicated by lower HbA1c (eTable

2). For sensitivity analyses, we used three *GLP1R* SNPs for BMI and two *GLP1R* SNPs for

HbA1c based on a more lenient significance threshold (p value $< 1 \times 10^{-5}$) (eTable 2). The

GLP1R SNPs for BMI were not associated with HbA1c and vice versa (eTable 3), which

substantiated that the two sets of genetic instruments represent distinct mechanisms of GLP-

1R activation.[30] For comparison, we also extracted 516 (overall), 303 (women), and 256

(men) SNPs for BMI and 318 (overall), 200 (women), 174 (men) SNPs for HbA1c from

across the genome (eTable 4). The F-statistics of the primary instruments were all >10

(eTables 2 and 4).

In positive control analyses, genetically predicted lower BMI and lower HbA1c via GLP-1R

activation were associated with lower CAD risk and all-cause mortality, despite wide

confidence intervals (CIs) (eFigure 1). The point estimates for GLP-1R activation were

comparable to those for genetically predicted lower BMI and lower HbA1c based on genome-

wide variants (eFigure 1 and eTable 5).

Associations of GLP-1R activation with mental health well-being

Genetically predicted lower BMI via GLP-1R activation was associated with a better well-

being spectrum, including life satisfaction, positive affect, neuroticism, and depressive

symptoms (Figure 1). The association with depressive symptoms was evident specifically in

women (eFigure 2). These associations were stronger than the associations for genetically

predicted lower BMI using genome-wide variants (Figure 1). However, genetically predicted

lower HbA1c via GLP-1R activation had little association with mental health well-being

(Figure 1). Sensitivity analyses gave consistent estimates, and the Steiger filtering identified

no SNP that explained more variance in the outcome than in the exposure (eTable 6-7).

Associations of GLP-1R activation with the risk of mental health disorders

Genetically predicted lower BMI via GLP-1R activation was associated with lower risk of

depression, postpartum depression, bipolar disorder, bipolar disorder I and II, and ADHD

(Figure 2). The association with depression was possibly stronger in women than men,

although the *p* value for sex difference was 0.35 (eFigure 3). These associations were stronger

than the associations for genetically predicted lower BMI using genome-wide variants (Figure

2). Genetically predicted lower HbA1c via GLP-1R activation was associated with higher risk

of anorexia nervosa but lower risk of Tourette syndrome, with stronger associations than the

associations for genetically predicted lower HbA1c using genome-wide variants (Figure 2).

These results were robust to different MR methods and the exclusion of SNPs identified by

the Steiger filtering (eTable 8).

Associations of GLP-1R activation with the risk of substance use disorders

Genetically predicted lower BMI via GLP-1R activation was associated with lower risk of

substance use disorders and lower AUDIT score for alcohol problems (Figure 3). These

associations were stronger than the associations for genetically predicted lower BMI using

genome-wide variants. However, genetically predicted lower HbA1c via GLP-1R activation

had little association with the risk of substance use disorders (Figure 3). Sensitivity analyses

using different MR methods and excluding the SNPs identified by the Steiger filtering gave

similar interpretations (eTable 9).

Replication

In FinnGen, genetically predicted lower BMI via GLP-1R activation was associated with

lower risk of depression, bipolar disorder, PTSD, ADHD, substance abuse, and alcohol

dependence (eFigure 4). Genetically predicted lower HbA1c via GLP-1R activation had little

association with mental health outcomes except for depression (eFigure 4). Nevertheless, this

association with depression was attenuated to null when using the two SNPs extracted based

on a more lenient significance threshold (eTable 10).

Colocalization

After correcting for multiple comparisons, genetically predicted lower BMI via GLP-1R

activation remained significantly associated with the well-being spectrum, life satisfaction,

positive affect, neuroticism, depressive symptoms, depression, bipolar disorder, and bipolar

disorder I (p values <0.005). Pairwise colocalization analyses were performed for BMI and

each significant outcome in or near the *GLP1R* gene. The posterior probabilities of

colocalization were <80% for all the significant outcomes (Figure 4). However, conditioning

on the presence of a variant associated with the outcome, the posterior probabilities of

colocalization were all >80% except for depression (Figure 4), suggesting that some lack of

colocalization was due to limited power. The posterior probabilities of two independent

variants associated with each trait were <15% for all the significant outcomes (eTable 11),

suggesting that confounding by linkage disequilibrium was unlikely. Across the *GLP1R* gene

region, rs4714290, rs847784 (a proxy for rs4714290, $r^2 = 0.89$), or rs17757975 had the largest

posterior probability of being the shared causal variant, which substantiated their validity as

genetic instruments.

Multi-trait colocalization analyses were performed across BMI and all the significant

outcomes in or near the *GLP1R* gene. We identified BMI, the well-being spectrum, life

satisfaction, positive affect, neuroticism, depressive symptoms as a cluster of putatively

colocalized traits with the posterior probability of colocalization 51.9%.

Discussion

This drug-target MR study suggests that GLP-1R activation is associated with a better well-

being spectrum and lower risk of bipolar disorder. We also provide suggestive evidence that

GLP-1R activation is associated with lower risk of substance use disorders. These

associations are likely beyond the effects of GLP-1R activation on BMI and HbA1c.

We found that genetically predicted GLP-1R activation was associated with a better well-being spectrum, lower risk of depression, and lower risk of bipolar disorder. Consistently, RCTs have shown that GLP-1R agonists moderately reduce depression symptoms in overweight people[12] and in people with type 2 diabetes.[13] A small open-label trial showed that liraglutide, as an adjunct to existing pharmacotherapy, improved cognitive function[60] and brain volumes[61] in people with depression or bipolar disorder. These psychiatric benefits of GLP-1R activation could be driven by the neuroprotective effects of GLP-1 including enhanced neurogenesis, improved barrier function, reduced neuroinflammation, and decreased oxidative stress.[62]

Interestingly, the associations of GLP-1R activation with favorable mental health outcomes were more evident when proxied via BMI than via HbA1c, highlighting the importance of BMI-related mechanisms. A recent study showed that GLP-1R agonists target the hindbrain dorsal vagal complex to decrease food intake and body weight.[4] Actions on the hypothalamus and vagal afferents also contribute to the weight loss on GLP-1R agonists.[5,6] GLP neurons in the dorsal vagal complex moderate stress responses and stimulate hypothalamic-pituitary-adrenal (HPA) axis activity, which has been implicated in the pathology of depression[63] and bipolar disorder.[64] Notably, the HPA axis is also related to cognitive function,[63,64] consistent with an RCT showing that dulaglutide reduces cognitive impairment in people with type 2 diabetes.[65] Additional studies are warranted to elucidate the mechanisms underlying potential

benefits of GLP-1R agonists for mental health.

We found that genetically predicted GLP-1R activation was possibly associated with lower

risk of depression specifically in women and lower risk of postpartum depression. We caution

that the power to detect sex differences may have been limited by small or unequal sample

sizes of sex-stratified GWAS. Women are about twice as likely as men to have depression

during their lifetime with the difference starting at puberty.[25] A meta-analysis of RCTs showed

that GLP-1R agonists decreased testosterone and increased sex hormone-binding globulin in

women with polycystic ovary syndrome,[66] but their effects on estrogen are less clear. Sex

hormones might contribute to GLP-1R activation improving depression in women, given their

potential roles in modulating serotonergic neurotransmission, cortisol, and oxytocin.[67]

Genetically predicted GLP-1R activation was suggestively associated with lower risk of

ADHD and Tourette syndrome but had a null association with autism spectrum disorder.

Although RCTs have shown the short-term (no more than 26 weeks) safety of GLP-1R

agonists in children and adolescents,[68] RCTs typically do not capture the long latency of

neurodevelopmental disorders. Our study adds to the evidence by showing little adverse effect

of lifelong GLP-1R activation on these disorders. However, GLP-1R activation was

associated with higher risk of anorexia nervosa when proxied via HbA1c. GLP-1R activation

increases insulin secretion and sensitivity and lowers glucose.[69] A previous MR study

suggested an inverse association of fasting insulin with the risk of anorexia nervosa,[70]

indicating a role of insulin sensitivity.

We provide suggestive evidence that GLP-1R activation was associated with lower risk of

substance use disorders and lower AUDIT score for alcohol problems, which were replicated

in FinnGen. Our finding aligns with a recent RCT showed that eight-week treatment with

semaglutide reduced alcohol consumption and craving in people with alcohol use disorder.[20]

In contrast, another RCT including people with alcohol use disorder showed that 26 weeks of

treatment with exenatide did not significantly reduce heavy drinking days, although exenatide

attenuated fMRI alcohol cue reactivity in brain areas for drug reward and addiction.[19] Further

evidence from RCTs is needed to determine the repurposing opportunities of GLP-1R

agonists for treating substance use disorders.

We presented the MR estimates of GLP-1R activation in effect sizes of BMI or HbA1c

reduction for interpretability. However, this scaling does not imply that weight loss or glucose

lowering is the sole mechanism of action for the psychiatric effects of GLP-1R activation.

Indeed, the associations of GLP-1R activation with mental health outcomes appeared stronger

than those expected from lowering BMI and HbA1c. Correspondingly, RCTs have showed

that semaglutide reduces cardiovascular events and mortality more than expected from the

reduction in body weight,[12] and that GLP-1R agonists outperform other anti-diabetes drugs.[71]

Apart from reducing body weight and glucose, GLP-1R agonists also decrease blood pressure,

low-density lipoprotein cholesterol, and inflammation and enhance kidney function.[2,3] The

multifaceted effects of GLP-1R agonists could be partially explained by 5' adenosine

monophosphate-activated protein kinase (AMPK) activation.[72] Taken together, our findings

suggest that the psychiatric benefits of GLP-1R activation likely extend beyond its effect on

BMI and HbA1c.

This drug-target MR study comprehensively explored the associations of GLP-1R activation

with mental health outcomes. Our investigation has implications for the psychiatric safety and

repurposing opportunities of GLP-1R agonists, particularly in people with mental health

disorders, who usually have higher risk of obesity and type 2 diabetes but are undertreated.

This study has several limitations. First, MR relies on three rigorous assumptions, that is

genetic instruments should be related to the exposure, share no common cause with the

outcome, and be independent of the outcome given the exposure.[23] The F-statistics were >10,

suggesting minimal weak instrument bias. We validated the genetic instruments using CAD

and all-cause mortality as positive control outcomes. We used MR methods with different

assumptions about instrumental validity, which gave consistent estimates. Second, we selected

genetic instruments for GLP-1R activation based on their associations with BMI and HbA1c,

but additional underlying factors may explain their psychiatric effects. Instrumenting on BMI

and HbA1c could have masked some effects of GLP-1R activation. Third, the small number

of genetic instruments for GLP-1R activation, even when applying a more lenient significance

threshold for instrument selection, may have limited the detection of possible causal effects.

Fourth, we obtained genetic associations with BMI from a meta-analysis of the UK Biobank

and GIANT and with HbA1c from the UK Biobank, which overlaps with some outcome

GWASs. Two-sample MR methods in a one-sample setting perform well in terms of bias and

precision in large biobanks, except for MR Egger which can result in bias reflecting the

direction and magnitude of confounding.[73] We replicated the results using outcome GWASs

from FinnGen, which has no overlap with the UK Biobank or GIANT. Fifth, the power to

detect colocalization was insufficient. However, the posterior probabilities of two independent

variants associated with each trait were <15% for all the significant outcomes, suggesting that

the associations found were unlikely driven by confounding due to linkage disequilibrium.

Sixth, MR can be open to selection bias from selecting on genetic makeup and mental health

disorders. Nevertheless, such selection should bias towards a harmful effect of GLP-1R

activation, which could not explain its associations with favorable mental health outcomes.

Finally, mental health disorders sometimes originate during childhood or adolescence, but

GLP-1R agonists are primarily used in adults. Our MR study assessed lifelong effects of

GLP-1R activation, which cannot directly inform the short-term effects of GLP-1R agonists.

RCTs are warranted to determine the clinical relevance of these findings in the future.

Conclusions

378 This drug-target MR study provides genetic evidence that GLP-1R activation is associated

379 with better mental health well-being and lower risk of bipolar disorder, possibly beyond its

380 effect on BMI and HbA1c.

Acknowledgements

383 The authors acknowledge Pulit SL, et al., the Neale lab, the CARDIoGRAMplusC4D

384 Consortium, Timmers PR, et al., Baselmans BML, et al., the Psychiatric Genomics

385 Consortium, and FinnGen for their publicly available summary data.

Funding

388 GY is supported by the American Heart Association Postdoctoral Fellowship

389 (26POST1560184). SB is supported by the Wellcome Trust (225790/Z/22/Z) and the United

390 Kingdom Research and Innovation Medical Research Council (MC_UU_00002/7). The

391 funders had no role in the study design, analyses, or interpretation of results.

Competing interests

394 The authors declared no conflict of interest.

Availability of data and materials

Summary statistics analyzed are available in the website

https://doi.org/10.5281/zenodo.1251813 for BMI, http://www.nealelab.is/uk-biobank/ for

HbA1c, https://www.cardiogramplusc4d.org/data-downloads/ for CAD,

https://www.ebi.ac.uk/gwas/publications/30642433 for parental mortality,

https://www.ebi.ac.uk/gwas/publications/30643256 for mental health well-being, and

https://pgc.unc.edu/for-researchers/download-results/ and

https://www.finngen.fi/en/access_results for mental health disorders and substance use

disorders.

Author contributions

407   GY and CMS designed the study. GY undertook analyses with feedback from SB and CMS.

408   GY drafted the manuscript with critical feedback and revisions from SB and CMS. All authors

409   read and approved the final version of the manuscript. GY had full access to all the data in the

410   study and takes responsibility for the integrity of the data and the accuracy of the data

411   analysis.

Artificial intelligence (AI)-assisted technologies

414   The authors declared that AI-assisted technologies were not used in this study.

References

1. Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. *Nature reviews Endocrinology.* 2018;14(7):390-403.

2. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *N Engl J Med.* 2023;389(24):2221-2232.

3. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *The lancet Diabetes & endocrinology.* 2021;9(10):653-662.

4. Huang KP, Acosta AA, Ghidewon MY, et al. Dissociable hindbrain GLP1R circuits for satiety and aversion. *Nature.* 2024.

5. Burmeister MA, Ayala JE, Smouse H, et al. The Hypothalamic Glucagon-Like Peptide 1 Receptor Is Sufficient but Not Necessary for the Regulation of Energy Balance and Glucose Homeostasis in Mice. *Diabetes.* 2017;66(2):372-384.

6. Krieger JP, Arnold M, Pettersen KG, Lossel P, Langhans W, Lee SJ. Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia. *Diabetes.* 2016;65(1):34-43.

7. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. *Lancet (London, England).* 2011;377(9774):1341-1352.

8.   Topol EJ, Bousser MG, Fox KA, et al. Rimonabant for prevention of cardiovascular

events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. *Lancet*

(London, England). 2010;376(9740):517-523.

9.   Pi-Sunyer X, Apovian CM, McElroy SL, Dunayevich E, Acevedo LM, Greenway FL.

Psychiatric adverse events and effects on mood with prolonged-release

naltrexone/bupropion combination therapy: a pooled analysis. *International journal of*

obesity (2005). 2019;43(10):2085-2094.

10.   Trivedi MH, Walker R, Ling W, et al. Bupropion and Naltrexone in Methamphetamine

Use Disorder. *The New England journal of medicine*. 2021;384(2):140-153.

11.   European Medicines Agency. EMA statement on ongoing review of GLP-1 receptor

agonists. 2023; https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-

glp-1-receptor-agonists. Accessed September 20, 2024.

12.   Wadden TA, Brown GK, Egebjerg C, et al. Psychiatric Safety of Semaglutide for

Weight Management in People Without Known Major Psychopathology: Post Hoc

Analysis of the STEP 1, 2, 3, and 5 Trials. *JAMA internal medicine*. 2024.

13.   Chen X, Zhao P, Wang W, Guo L, Pan Q. The Antidepressant Effects of GLP-1

Receptor Agonists: A Systematic Review and Meta-Analysis. *The American journal of*

geriatric psychiatry : official journal of the American Association for Geriatric

Psychiatry. 2024;32(1):117-127.

14.   Suchankova P, Yan J, Schwandt ML, et al. The glucagon-like peptide-1 receptor as a

potential treatment target in alcohol use disorder: evidence from human genetic

association studies and a mouse model of alcohol dependence. *Translational*

psychiatry. 2015;5(6):e583.

15. Aranäs C, Edvardsson CE, Shevchouk OT, et al. Semaglutide reduces alcohol intake

and relapse-like drinking in male and female rats. *EBioMedicine.* 2023;93:104642.

16. Wium-Andersen IK, Wium-Andersen MK, Fink-Jensen A, Rungby J, Jørgensen MB,

Osler M. Use of GLP-1 receptor agonists and subsequent risk of alcohol-related

events. A nationwide register-based cohort and self-controlled case series study. *Basic*

& clinical pharmacology & toxicology. 2022;131(5):372-379.

17. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of

semaglutide with incidence and recurrence of alcohol use disorder in real-world

population. *Nature communications.* 2024;15(1):4548.

18. Reitz J, Rosoff DB, Perlstein T, et al. Genetically modeled GLP1R and GIPR agonism

reduce binge drinking and alcohol-associated phenotypes: a multi-ancestry drug-target

Mendelian randomization study. *Mol Psychiatry.* 2025.

19. Klausen MK, Jensen ME, Møller M, et al. Exenatide once weekly for alcohol use

disorder investigated in a randomized, placebo-controlled clinical trial. *JCI insight.*

2022;7(19).

20. Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in

Adults With Alcohol Use Disorder: A Randomized Clinical Trial. *JAMA Psychiatry.*

2025;82(4):395-405.

21. Ganeshalingam AA, Uhrenholt NG, Arnfred S, Gæde PH, Bilenberg N, Frystyk J.

Home-based Intervention with Semaglutide Treatment of Neuroleptic-Related

Prediabetes (HISTORI): protocol describing a prospective, randomised, placebo

controlled and double-blinded multicentre trial. *BMJ open.* 2024;14(3):e077173.

22.   Köhne S, Hillemacher T, Glahn A, Bach P. Emerging drugs in phase II and III clinical

development for the treatment of alcohol use disorder. *Expert opinion on emerging*

drugs. 2024;29(3):219-232.

23.   Didelez V, Sheehan N. Mendelian randomization as an instrumental variable approach

to causal inference. *Statistical methods in medical research.* 2007;16(4):309-330.

24.   Giambartolomei C, Vukcevic D, Schadt EE, et al. Bayesian test for colocalisation

between pairs of genetic association studies using summary statistics. *PLoS genetics.*

2014;10(5):e1004383.

25.   Kuehner C. Why is depression more common among women than among men? *The*

lancet Psychiatry. 2017;4(2):146-158.

26.   Bölte S, Neufeld J, Marschik PB, Williams ZJ, Gallagher L, Lai MC. Sex and gender

in neurodevelopmental conditions. *Nature reviews Neurology.* 2023;19(3):136-159.

27.   Gill D, Dib MJ, Cronjé HT, et al. Common pitfalls in drug target Mendelian

randomization and how to avoid them. *BMC medicine.* 2024;22(1):473.

28.   Locke AE, Kahali B, Berndt SI, et al. Genetic studies of body mass index yield new

insights for obesity biology. *Nature.* 2015;518(7538):197-206.

29.   UK Biobank (Neale lab). http://www.nealelab.is/uk-biobank/.

30.   Patel A, Gill D, Shungin D, et al. Robust use of phenotypic heterogeneity at drug

target genes for mechanistic insights: Application of cis-multivariable Mendelian

randomization to GLP1R gene region. *Genetic epidemiology.* 2024;48(4):151-163.

31.   Aragam KG, Jiang T, Goel A, et al. Discovery and systematic characterization of risk

variants and genes for coronary artery disease in over a million participants. *Nat*

Genet. 2022;54(12):1803-1815.

32.   Timmers PR, Mounier N, Lall K, et al. Genomics of 1 million parent lifespans

implicates novel pathways and common diseases and distinguishes survival chances.

eLife. 2019;8.

33.   Baselmans BML, Jansen R, Ip HF, et al. Multivariate genome-wide analyses of the

well-being spectrum. *Nature genetics.* 2019;51(3):445-451.

34.   Howard DM, Adams MJ, Clarke TK, et al. Genome-wide meta-analysis of depression

identifies 102 independent variants and highlights the importance of the prefrontal

brain regions. *Nature neuroscience.* 2019;22(3):343-352.

35.   Guintivano J, Byrne EM, Kiewa J, et al. Meta-Analyses of Genome-Wide Association

Studies for Postpartum Depression. *The American journal of psychiatry.*

2023;180(12):884-895.

36.   Mullins N, Forstner AJ, O'Connell KS, et al. Genome-wide association study of more

than 40,000 bipolar disorder cases provides new insights into the underlying biology.

Nature genetics. 2021;53(6):817-829.

37.   Nievergelt CM, Maihofer AX, Klengel T, et al. International meta-analysis of PTSD

genome-wide association studies identifies sex- and ancestry-specific genetic risk loci.

Nature communications. 2019;10(1):4558.

38.   Trubetskoy V, Pardiñas AF, Qi T, et al. Mapping genomic loci implicates genes and

synaptic biology in schizophrenia. *Nature.* 2022;604(7906):502-508.

39.   Watson HJ, Yilmaz Z, Thornton LM, et al. Genome-wide association study identifies

eight risk loci and implicates metabo-psychiatric origins for anorexia nervosa. *Nature*

genetics. 2019;51(8):1207-1214.

40.   Demontis D, Walters GB, Athanasiadis G, et al. Genome-wide analyses of ADHD

identify 27 risk loci, refine the genetic architecture and implicate several cognitive

domains. *Nature genetics.* 2023;55(2):198-208.

41.   Martin J, Walters RK, Demontis D, et al. A Genetic Investigation of Sex Bias in the

Prevalence of Attention-Deficit/Hyperactivity Disorder. *Biological psychiatry.*

2018;83(12):1044-1053.

42.   Grove J, Ripke S, Als TD, et al. Identification of common genetic risk variants for

autism spectrum disorder. *Nature genetics.* 2019;51(3):431-444.

43.   Yu D, Sul JH, Tsetsos F, et al. Interrogating the Genetic Determinants of Tourette's

Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. *The*

American journal of psychiatry. 2019;176(3):217-227.

44.   Hatoum AS, Colbert SMC, Johnson EC, et al. Multivariate genome-wide association

meta-analysis of over 1 million subjects identifies loci underlying multiple substance

use disorders. *Nature Mental health.* 2023;1(3):210-223.

45.   Johnson EC, Demontis D, Thorgeirsson TE, et al. A large-scale genome-wide

association study meta-analysis of cannabis use disorder. *The lancet Psychiatry.*

2020;7(12):1032-1045.

46.   Walters RK, Polimanti R, Johnson EC, et al. Transancestral GWAS of alcohol

dependence reveals common genetic underpinnings with psychiatric disorders. *Nature*

neuroscience. 2018;21(12):1656-1669.

47.   Sanchez-Roige S, Palmer AA, Fontanillas P, et al. Genome-Wide Association Study

Meta-Analysis of the Alcohol Use Disorders Identification Test (AUDIT) in Two

Population-Based Cohorts. *The American journal of psychiatry.* 2019;176(2):107-118.

48.   Kurki MI, Karjalainen J, Palta P, et al. FinnGen provides genetic insights from a well-

phenotyped isolated population. *Nature.* 2023;613(7944):508-518.

49.   Lloyd-Jones LR, Robinson MR, Yang J, Visscher PM. Transformation of Summary

Statistics from Linear Mixed Model Association on All-or-None Traits to Odds Ratio.

Genetics. 2018;208(4):1397-1408.

50.   Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan NA, Thompson JR.

Assessing the suitability of summary data for two-sample Mendelian randomization

analyses using MR-Egger regression: the role of the I2 statistic. *International journal*

of epidemiology. 2016;45(6):1961-1974.

51.   Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with

multiple genetic variants using summarized data. *Genetic epidemiology.*

2013;37(7):658-665.

52.   Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in

Mendelian Randomization with Some Invalid Instruments Using a Weighted Median

Estimator. *Genetic epidemiology.* 2016;40(4):304-314.

53.   Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid

instruments: effect estimation and bias detection through Egger regression.

International journal of epidemiology. 2015;44(2):512-525.

54.   Qingyuan Z, Jingshu W, Gibran H, Jack B, Dylan SS. Statistical inference in two-

sample summary-data Mendelian randomization using robust adjusted profile score.

The Annals of Statistics. 2020;48(3):1742-1769.

55.   Greco MF, Minelli C, Sheehan NA, Thompson JR. Detecting pleiotropy in Mendelian

randomisation studies with summary data and a continuous outcome. *Stat Med.*

2015;34(21):2926-2940.

56.   Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between

imprecisely measured traits using GWAS summary data. *PLoS genetics.*

2017;13(11):e1007081.

57.   Altman DG, Bland JM. Interaction revisited: the difference between two estimates.

BMJ (Clinical research ed). 2003;326(7382):219.

58.   Zuber V, Grinberg NF, Gill D, et al. Combining evidence from Mendelian

randomization and colocalization: Review and comparison of approaches. *American*

journal of human genetics. 2022;109(5):767-782.

59.   Foley CN, Staley JR, Breen PG, et al. A fast and efficient colocalization algorithm for

identifying shared genetic risk factors across multiple traits. *Nature communications.*

2021;12(1):764.

60.   Mansur RB, Ahmed J, Cha DS, et al. Liraglutide promotes improvements in objective

measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-

label study. *Journal of affective disorders.* 2017;207:114-120.

61.   Mansur RB, Zugman A, Ahmed J, et al. Treatment with a GLP-1R agonist over four

weeks promotes weight loss-moderated changes in frontal-striatal brain structures in

individuals with mood disorders. *European neuropsychopharmacology : the journal of*

the European College of Neuropsychopharmacology. 2017;27(11):1153-1162.

62.   Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions

of GIP and GLP1. *Nature reviews Endocrinology.* 2023;19(4):201-216.

63.   Keller J, Gomez R, Williams G, et al. HPA axis in major depression: cortisol, clinical

symptomatology and genetic variation predict cognition. *Molecular psychiatry.*

2017;22(4):527-536.

64.   Belvederi Murri M, Prestia D, Mondelli V, et al. The HPA axis in bipolar disorder:

Systematic review and meta-analysis. *Psychoneuroendocrinology.* 2016;63:327-342.

65.   Cukierman-Yaffe T, Gerstein HC, Colhoun HM, et al. Effect of dulaglutide on

cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial.

The Lancet Neurology. 2020;19(7):582-590.

66.   Zhou L, Qu H, Yang L, Shou L. Effects of GLP1RAs on pregnancy rate and menstrual

cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic

review. *BMC endocrine disorders.* 2023;23(1):245.

67.   Martel MM. Sexual selection and sex differences in the prevalence of childhood

externalizing and adolescent internalizing disorders. *Psychological bulletin.*

2013;139(6):1221-1259.

68.   Yugar LBT, Sedenho-Prado LG, da Silva Ferreira IMC, Silva CAM, Sposito AC,

Cercato C. The efficacy and safety of GLP-1 receptor agonists in youth with type 2

diabetes: a meta-analysis. *Diabetology & metabolic syndrome.* 2024;16(1):92.

69.   MacDonald PE, El-Kholy W, Riedel MJ, Salapatek AM, Light PE, Wheeler MB. The

multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion.

Diabetes. 2002;51 Suppl 3:S434-442.

70.   Adams DM, Reay WR, Geaghan MP, Cairns MJ. Investigation of glycaemic traits in

psychiatric disorders using Mendelian randomisation revealed a causal relationship

with anorexia nervosa. *Neuropsychopharmacology : official publication of the*

American College of Neuropsychopharmacology. 2021;46(6):1093-1102.

71.   Shi Q, Nong K, Vandvik PO, et al. Benefits and harms of drug treatment for type 2

diabetes: systematic review and network meta-analysis of randomised controlled trials.

BMJ (Clinical research ed). 2023;381:e074068.

72.   Schooling CM, Yang G, Soliman GA, Leung GM. A Hypothesis That Glucagon-like

Peptide-1 Receptor Agonists Exert Immediate and Multifaceted Effects by Activating

Adenosine Monophosphate-Activate Protein Kinase (AMPK). *Life (Basel,*

Switzerland). 2025;15(2).

73.   Minelli C, Del Greco MF, van der Plaat DA, Bowden J, Sheehan NA, Thompson J.

The use of two-sample methods for Mendelian randomization analyses on single large

datasets. *International journal of epidemiology.* 2021.

Figure 1. IVW MR estimates for the associations of GLP-1R activation with mental health well-being.

BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated hemoglobin; IVW, inverse variance weighted; MR,

Mendelian randomization. Black squares denote genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on

GLP1R variants. White circles denote genetically predicted (a) lower BMI or (b) lower HbA1c based on genome-wide variants. Positive

associations with the well-being spectrum, life satisfaction, and positive affect and negative associations with neuroticism and depressive

symptoms indicate better mental health well-being. Estimates are presented in standard deviation units for mental health well-being per 1-kg/m^2

decrease in BMI or per 1-mmol/mol decrease in HbA1c.

(a) BMI lowering

■ Lower BMI by GLP-1R activation ⊖ Lower BMI

(b) HbA1c lowering

■ Lower HbA1c by GLP-1R activation ⊖ Lower HbA1c

Outcome	Case/control	Odds ratio (95% CI) [BMI]	P value [BMI]	Odds ratio (95% CI) [HbA1c]	P value [HbA1c]
Depression	170,756/329,443	0.83 (0.74 to 0.94)	.003	1.03 (0.94 to 1.13)	.54
		0.98 (0.97 to 0.99)	<.001	1.00 (1.00 to 1.00)	.90
Post-partum depression	17,339/53,426	0.62 (0.43 to 0.89)	.01	0.83 (0.61 to 1.14)	.25
		0.98 (0.96 to 1.00)	.03	1.00 (0.99 to 1.01)	.41
Bipolar disorder	41,917/371,549	0.61 (0.47 to 0.79)	<.001	1.19 (0.97 to 1.46)	.09
		1.00 (0.98 to 1.02)	.77	1.01 (0.99 to 1.02)	.34
Bipolar disorder I	25,060/449,978	0.58 (0.42 to 0.80)	<.001	1.18 (0.92 to 1.53)	.20
		1.01 (0.98 to 1.03)	.57	1.01 (1.00 to 1.02)	.25
Bipolar disorder II	6,781/364,075	0.56 (0.32 to 0.97)	.04	1.47 (0.93 to 2.33)	.10
		1.00 (0.97 to 1.03)	.94	1.00 (0.99 to 1.02)	.86
PTSD	23,212/151,447	0.71 (0.47 to 1.07)	.10	1.24 (0.88 to 1.74)	.22
		0.94 (0.92 to 0.96)	<.001	1.00 (0.99 to 1.01)	.64
Schizophrenia	53,386/77,258	0.88 (0.69 to 1.11)	.28	1.13 (0.93 to 1.37)	.21
		1.03 (1.01 to 1.05)	.01	1.00 (0.99 to 1.01)	.45
Anorexia nervosa	16,992/55,525	0.95 (0.65 to 1.39)	.79	1.53 (1.13 to 2.09)	.007
		1.10 (1.07 to 1.12)	<.001	1.02 (1.00 to 1.03)	.02
ADHD	38,691/186,843	0.72 (0.55 to 0.94)	.01	0.89 (0.73 to 1.09)	.27
		0.89 (0.87 to 0.90)	<.001	0.99 (0.98 to 1.00)	.02
Autism spectrum disorder	18,381/27,969	0.69 (0.47 to 1.02)	.06	0.75 (0.55 to 1.03)	.07
		0.98 (0.95 to 1.00)	.05	1.00 (0.99 to 1.02)	.43
Tourette syndrome	4,819/9,488	1.27 (0.62 to 2.59)	.52	0.54 (0.31 to 0.94)	.03
		0.97 (0.93 to 1.01)	.14	0.99 (0.97 to 1.01)	.18

Axis: 0.4 0.6 1.0 1.6 2.7

Figure 2. IVW MR estimates for the associations of GLP-1R activation with the risk of mental health disorders.

638   ADHD, attention deficit hyperactivity disorder; BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated

639   hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization; PTSD, post-traumatic stress disorder. Black squares denote

640   genetically predicted (a) lower BMI or (b) lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically

641   predicted (a) lower BMI or (b) lower HbA1c based on genome-wide variants. Estimates are presented as odds ratio per 1-kg/m^2 decrease in BMI

642   or per 1-mmol/mol decrease in HbA1c.

(a) BMI lowering

■ Lower BMI by GLP-1R activation   ⊖ Lower BMI

(b) HbA1c lowering

■ Lower HbA1c by GLP-1R activation   ⊖ Lower HbA1c

Outcome	N (case/control)	Beta (95% CI) (a)	P value (a)	Beta (95% CI) (b)	P value (b)
Substance use disorders	1,025,550	-0.12 (-0.21 to -0.03)	.007	-0.004 (-0.05 to 0.05)	.87
		-0.01 (-0.02 to -0.01)	<.001	-0.001 (-0.00 to 0.00)	.49
Cannabis use disorder	14,080/343,726	-0.28 (-0.75 to 0.19)	.24	0.23 (-0.14 to 0.61)	.22
		-0.06 (-0.08 to -0.03)	<.001	-0.01 (-0.02 to 0.00)	.17
Alcohol dependence	8,485/20,272	-0.23 (-0.83 to 0.38)	.46	-0.27 (-0.78 to 0.24)	.30
		-0.01 (-0.05 to 0.02)	.35	0.002 (-0.02 to 0.02)	.86
AUDIT (total score)	121,604	-0.03 (-0.06 to 0.00)	.06	0.02 (-0.01 to 0.04)	.23
		0.003 (0.00 to 0.01)	.01	0.001 (0.00 to 0.00)	.02
AUDIT (alcohol consumption)	121,604	-0.02 (-0.05 to 0.01)	.17	0.02 (-0.01 to 0.04)	.13
		0.003 (0.00 to 0.01)	.001	0.001 (0.00 to 0.00)	.008
AUDIT (alcohol problems)	121,604	-0.03 (-0.06 to -0.00)	.04	0.01 (-0.01 to 0.03)	.35
		-0.001 (-0.00 to 0.00)	.16	0.000 (-0.00 to 0.00)	.78

(a) axis: -1, -0.5, 0, 0.5 (b) axis: -1, -0.5, 0, 0.5

Figure 3. IVW MR estimates for the associations of GLP-1R activation with the risk of substance use disorders and AUDIT scores.

AUDIT, Alcohol Use Disorders Identification Test; BMI, body mass index; GLP-1R, glucagon-like peptide-1 receptor; HbA1c, glycated

hemoglobin; IVW, inverse variance weighted; MR, Mendelian randomization. Black squares denote genetically predicted (a) lower BMI or (b)

lower HbA1c via GLP-1R activation based on *GLP1R* variants. White circles denote genetically predicted (a) lower BMI or (b) lower HbA1c

based on genome-wide variants. Positive associations with AUDIT scores indicate higher risk of alcohol use disorders. Estimates are presented in

standard deviation unit for substance use disorder risk, as logodds for cannabis use disorder and alcohol dependence, and as log10 transformed

score for AUDIT scores per 1-kg/m^2 decrease in BMI or per 1-mmol/mol decrease in HbA1c.

Figure 4. Pairwise colocalization analyses for BMI and each significant outcome at the *GLP1R* gene.

BMI, body mass index. Probability for colocalization means the posterior probability of a shared variant associated with both traits; conditional

probability means the posterior probability of a shared variant associated with both traits conditional on the presence of a variant associated with

the outcome. Given the presence of a shared variant associated with both traits, the labeled variant had the largest probability of being the shared

causal variant.